Prairie Cancer Consortium
The overall vision of the Prairie Cancer Consortium (PR2C) is to create a collaborative, inclusive, equitable, and sustainable multiprovincial initiative that works towards developing new treatment strategies for patients facing cancer by enabling
precision cancer medicine research and accelerating its implementation into practice.
Officially designated as a part of the Marathon of Hope Cancer Centres Network in December 2021, the PR2C brings together researchers and clinicians from the following MOHCCN-member institutions: Arnie Charbonneau Cancer Institute, the University of Calgary, the Cancer Research Institute of
Northern Alberta, the University of Alberta, Alberta Health Services (Cancer Care Alberta; Cross Cancer Institute and Tom Baker Cancer Centre), the Saskatchewan Cancer Agency, University of Saskatchewan, Cancer Care Manitoba, and the University of
Manitoba. These members are supported by the Centre for Health Genomics and Informatics (CHGI) at the University of Calgary's Cumming School of Medicine, which provides all the sequencing for PR2C cohorts.
Goals and Objectives
Building on the unique expertise and infrastructure that already exists in the region, PR2C members will work towards three major goals:
- To accelerate the real-world application of precision oncology for cancer patients, including patients in rural and remote parts of the Prairies who may not have been eligible for clinical trials in the past;
- To strengthen the alignment between academic centres and health systems, supporting research that answers important clinical questions, now and in the future; and
- To train and educate the next generation of clinicians and scientists in precision oncology.
Partners
-
Member
-
Member
-
Member
-
Member
-
Member
-
Member
-
Member
Projects
-
Precision care and comprehensive research strategy for ovarian cancer patients: Beyond PARP inhibitors
Key ResearchersUsing molecular based tests to inform treatment for patients with advanced stage ovarian cancer following response to initial chemotherapy and/or surgery.Read more -
Characterizing genomic signatures in predicting renal cell carcinoma therapy response
Key ResearchersThe project seeks to characterize genomic backgrounds and biomarkers that could predict response or resistance to immunotherapy in patients with renal cell carcinoma.Read more -
Precision health based management of prostate cancer patients
Key ResearchersUsing advanced genomics and machine learning to better understand factors responsible for response/resistance to PARP and AKT inhibitors in prostate cancer patients to develop targeted therapies.Read more -
Precision target discovery in high-risk soft tissue sarcoma
Key ResearchersUsing genetic and molecular sequencing technologies to characterize the mutational and molecular profiles of high-risk soft-tissue sarcomas to advance precision therapies.Read more -
Searching for biomarkers associated with disease prognosis in patients with early-stage non-small cell lung cancer following surgery.Read more
-
Mapping the states of the glioblastoma cells in primary and recurrent tumours to understand how glioblastoma changes to escape current therapies and improve our ability to target relapsed tumours.Read more
-
Immunogenomics to decipher mediators of resistance to immune-mediated therapies in Multiple Myeloma
Key ResearchersDefining how the tumour microenvironment mediates response to immunotherapies in patients with multiple myeloma.Read more -
Investigating mechanisms of lymph node metastasis in oral cancer
Key ResearchersUsing genomics to understand progression and metastasis in Oral squamous cell carcinoma.Read more -
Young Women with Breast Cancer
Key ResearchersIdentifying potentially actionable targets and pathways involved in drug resistance and/or metastasis to guide treatment and inform prognosis for young females with breast cancer.Read more -
Understanding how chronic lymphocytic leukemia cells mutate in response to therapy in order to find better treatment options for patients.Read more
-
Using genomics to determine how glioblastoma cells evolve under the selective pressure of treatment with the goal of identifying new targets for intervention to help overcome therapeutic resistance.Read more
-
Predicting response to immune checkpoint blockades in high-grade soft tissue sarcomas
Key ResearchersCreating a computational tool to better understand which patients with soft-tissue sarcomas will respond to immunotherapies.Read more -
Creation of an advanced imaging, targeted biopsy, and genomic composite index to predict prostate cancer progression during active surveillance
Key ResearchersImproving risk assessment strategies to personalize care for patients with prostate cancerRead more -
A prospective study using a multi-omics approach to profile Manitobans with highly aggressive cancers to inform treatment and further research.Read more
Consortium Leadership
-
Hanne
Institutional LeadMOHCCN Steering CommitteeWorking Group Chair
Ostergaard -
Roseline
Institutional Lead
Godbout -
Paula
Institutional Lead
Robson -
Deborah
Institutional Lead
Anderson -
Lynn
Institutional Lead
Dwernychuk -
Shantanu
Institutional LeadProject LeaderWorking Group Member
Banerji -
Spencer
MOHCCN Network Council
Gibson -
Jennifer
MOHCCN Steering CommitteeConsortium LeaderProject LeaderWorking Group MemberResearcher
Chan
Project Management Team
-
Carolyn-Ann
Project ManagerWorking Group Member
Robinson
Project and Cohort Leaders
-
Shantanu
Institutional LeadProject LeaderWorking Group Member
Banerji -
Nizar
Project Leader
Bahlis -
Paola
Project Leader
Neri -
Sorana
Research LeadProject LeaderWorking Group Member
Morrissy -
Michael
Project Leader
Monument -
John
Project LeaderWorking Group Member
Lewis -
Tarek
Project Leader
Bismar -
Marshall
Project LeaderWorking Group Member
Pitz -
Jennifer
MOHCCN Steering CommitteeConsortium LeaderProject LeaderWorking Group MemberResearcher
Chan -
Laura
ResearcherProject Leader
Hopkins -
Daniel
ResearcherProject Leader
Heng -
Ana
ResearcherMOHCCN Clinician-Scientist Award Winner
Nikolic -
Pinaki
ResearcherProject Leader
Bose -
Martin
ResearcherProject Leader
Hyrcza -
Carrie
ResearcherProject Leader
Shemanko -
Afshin
ResearcherProject Leader
Raouf -
Versha
ResearcherProject Leader
Banerji -
Sachin
MOHCCN Steering CommitteeInstitutional LeadProject LeaderResearcher
Katyal
Related News
-
Prairie Cancer Consortium leadership and members share updates with the Network
The presentation was part of MOHCCN Seminar Series, which features virtual talks from MOHCCN research partner investigators and trainees, providing a platform for MOHCCN members to share their ongoing... -
Network names four outstanding early-career clinician-scientists as recipients of its 2024 MOHCCN Clinician-Scientist Awards
Four promising, early-career clinician-scientists from Alberta, Ontario and Quebec have been named recipients of the 2024 Clinician-Scientist Awards, funded by the Marathon of Hope Cancer Centres Netw... -
Meet the Team Canada of Cancer Research: A Q&A with Dr. Sachin Katyal
“The Network is enabling (even forcing!) researchers and clinicians together in a concerted way to communicate, innovate and action personalized cancer treatments,” says Dr. Sachin Katyal, institutional lead for CancerCare Manitoba, in our latest Q&A “The Network is enabling (even forcing!) researchers and clinicians together in a concerted way to communicate, innovate and action personalized cancer treatments,” says Dr. Sachin Katyal, institution... -
Network names 10 early-career data scientists as recipients of its 2024 Health Informatics & Data Science Awards
Each will receive $40,000 from the Network over the next year to be matched by their host institutions for a total of $80,000 to support groundbreaking research in precision oncology.